View Exam | PowerPak

1. Which of the following risk assessment tools has been validated to predict the risk of venous thromboembolism (VTE) in cancer patients based on the type of cancer, blood counts, and body mass index?

A. PROTECHT B. Vienna CATS C. Khorana D. TiC-ONCO

2. According to current guidelines, in which of the patients listed below might thromboprophylaxis be considered due to increased risk of VTE?

A. Ambulatory patient with multiple myeloma receiving lenalidomide B. Ambulatory patient with multiple myeloma receiving bortezomib C. Ambulatory patient with locally advanced prostate cancer receiving docetaxel D. Ambulatory patient with locally advanced prostate cancer receiving abiraterone acetate

3. Which of the following trials established low-molecular-weight heparin (LMWH) as the standard of care for treatment of cancer-associated VTE?

A. AMPLIFY B. CLOT C. Hokusai VTE Cancer D. EINSTEIN

4. According to outcomes from the Hokusai VTE Cancer (edoxaban), SELECT-D (rivaroxaban), and ADAM VTE (apixaban) trials, for a patient with which type of malignancy should you consider the risk-benefit profile due to a possible increased risk of gastrointestinal bleeding?

A. Breast B. Gastrointestinal C. Leukemia D. Lung

5. As part of the ADAM VTE (apixaban) trial, the investigators sought to determine the treatment satisfaction level among patients receiving a direct acting oral anticoagulant (DOAC) versus LMWH. Results reported from the ADAM VTE study revealed which of the following?

A. There was no significant difference in the rate of premature discontinuation B. The rate of premature discontinuation was significantly lower for patients using LMWH C. The rate of premature discontinuation was significantly lower for patients using the DOAC D. The rate of premature discontinuation was significantly higher for patients using the DOAC

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following risk assessment tools has been validated to predict the risk of venous thromboembolism (VTE) in cancer patients based on the type of cancer, blood counts, and body mass index?

2. According to current guidelines, in which of the patients listed below might thromboprophylaxis be considered due to increased risk of VTE?

3. Which of the following trials established low-molecular-weight heparin (LMWH) as the standard of care for treatment of cancer-associated VTE?

4. According to outcomes from the Hokusai VTE Cancer (edoxaban), SELECT-D (rivaroxaban), and ADAM VTE (apixaban) trials, for a patient with which type of malignancy should you consider the risk-benefit profile due to a possible increased risk of gastrointestinal bleeding?

5. As part of the ADAM VTE (apixaban) trial, the investigators sought to determine the treatment satisfaction level among patients receiving a direct acting oral anticoagulant (DOAC) versus LMWH. Results reported from the ADAM VTE study revealed which of the following?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following risk assessment tools has been validated to predict the risk of venous thromboembolism (VTE) in cancer patients based on the type of cancer, blood counts, and body mass index?

2. According to current guidelines, in which of the patients listed below might thromboprophylaxis be considered due to increased risk of VTE?

3. Which of the following trials established low-molecular-weight heparin (LMWH) as the standard of care for treatment of cancer-associated VTE?

4. According to outcomes from the Hokusai VTE Cancer (edoxaban), SELECT-D (rivaroxaban), and ADAM VTE (apixaban) trials, for a patient with which type of malignancy should you consider the risk-benefit profile due to a possible increased risk of gastrointestinal bleeding?

5. As part of the ADAM VTE (apixaban) trial, the investigators sought to determine the treatment satisfaction level among patients receiving a direct acting oral anticoagulant (DOAC) versus LMWH. Results reported from the ADAM VTE study revealed which of the following?

« Return to Activity

Customers who Purchased
this Activity also Purchased